Skip to main content
Erschienen in: Rheumatology International 7/2016

23.03.2016 | Observational Research

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome

verfasst von: Isha Saini, Mani Kalaivani, Sushil Kumar Kabra

Erschienen in: Rheumatology International | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim was to retrospectively estimate the prevalence of calcinosis in patients with juvenile dermatomyositis (JDM) and to identify risk factors associated with development of calcinosis in these patients. Retrospective chart review of 39 children diagnosed with JDM between 2004 and 2015 in a tertiary care hospital was done. Patients were divided into two groups, depending on the presence or absence of calcinosis, and the two groups were compared with respect to demographic, clinical, laboratory and therapeutic characteristics. Calcinosis developed in nine (23.1 %) patients. Delay in diagnosis and initiation of treatment, prolonged duration of disease, the presence of joint contractures and cardiac involvement were significantly associated with increased frequency of calcinosis. Six out of nine (66.7 %) patients with calcinosis received alendronate therapy, out of which four showed partial reduction in calcinosis. In one case, surgical removal of tumorous clumps was done. Calcinosis remains a common complication of JDM. We found an association between calcinosis and delay in diagnosis and initiation of treatment, prolonged duration of disease and cardiac involvement. Our study suggests that alendronate may be beneficial in management of calcinosis of JDM.
Literatur
1.
Zurück zum Zitat Rider LG, Lindsley CB, Cassidy JT (2005) Juvenile dermatomyositis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 375–413 Rider LG, Lindsley CB, Cassidy JT (2005) Juvenile dermatomyositis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 375–413
2.
Zurück zum Zitat Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441–446CrossRefPubMed Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441–446CrossRefPubMed
3.
Zurück zum Zitat Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S (2012) Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 41:50–58CrossRefPubMed Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S (2012) Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 41:50–58CrossRefPubMed
4.
Zurück zum Zitat Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48:1541–1547CrossRef Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48:1541–1547CrossRef
5.
Zurück zum Zitat Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldmen BM et al (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60:3425–3435CrossRefPubMedPubMedCentral Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldmen BM et al (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60:3425–3435CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62:63–72CrossRef Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62:63–72CrossRef
7.
Zurück zum Zitat Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM et al (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27:1031–1038PubMed Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM et al (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27:1031–1038PubMed
8.
Zurück zum Zitat Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124PubMed
9.
Zurück zum Zitat Efthimiou P, Kukar M, Kagen LJ (2010) Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol 37:194CrossRefPubMed Efthimiou P, Kukar M, Kagen LJ (2010) Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol 37:194CrossRefPubMed
10.
Zurück zum Zitat Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888CrossRefPubMed Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888CrossRefPubMed
11.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefPubMed
12.
Zurück zum Zitat Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766CrossRefPubMed Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766CrossRefPubMed
13.
Zurück zum Zitat Pachman LM, Boskey AL (2006) Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep 8:236–243CrossRefPubMed Pachman LM, Boskey AL (2006) Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep 8:236–243CrossRefPubMed
14.
Zurück zum Zitat Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511CrossRefPubMed Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511CrossRefPubMed
15.
Zurück zum Zitat Pachman LM, Maryjowski MC (1984) Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 10:95–115PubMed Pachman LM, Maryjowski MC (1984) Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 10:95–115PubMed
16.
Zurück zum Zitat Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28:833–857CrossRefPubMed Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28:833–857CrossRefPubMed
17.
Zurück zum Zitat Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549CrossRefPubMed
18.
Zurück zum Zitat Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterized by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol 12:2CrossRef Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterized by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol 12:2CrossRef
19.
Zurück zum Zitat Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729CrossRefPubMedPubMedCentral Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arthritis Rheum 37:R10ACrossRef Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arthritis Rheum 37:R10ACrossRef
21.
Zurück zum Zitat Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74CrossRef Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74CrossRef
22.
Zurück zum Zitat Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668–1678CrossRefPubMed Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668–1678CrossRefPubMed
23.
Zurück zum Zitat Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511–520CrossRefPubMed Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511–520CrossRefPubMed
24.
Zurück zum Zitat Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72CrossRefPubMed Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72CrossRefPubMed
25.
Zurück zum Zitat Marco Puche A, Calvo PI, Lopez MB (2010) Effectiveness of treatment with intravenous pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed Marco Puche A, Calvo PI, Lopez MB (2010) Effectiveness of treatment with intravenous pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140PubMed
26.
Zurück zum Zitat Ambler GR, Chaitow J, Rogers M, McDonald D, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed Ambler GR, Chaitow J, Rogers M, McDonald D, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839PubMed
Metadaten
Titel
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome
verfasst von
Isha Saini
Mani Kalaivani
Sushil Kumar Kabra
Publikationsdatum
23.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 7/2016
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3467-6

Weitere Artikel der Ausgabe 7/2016

Rheumatology International 7/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.